CLAIMS

1. A compound represented by the following general formula (I):



(I)

wherein

R^1 is a hydrogen atom or an optionally substituted C1-C3 alkyl group;

X is NR^2R^3, OR^4 or an optionally substituted monocyclic or polycyclic saturated or unsaturated heterocyclic group;

R^2 is a hydrogen atom or an optionally substituted C1-C6 alkyl group;

R^3 is a hydrogen atom, $C(=O)R^5$, $C(=S)R^6$, $S(=O)_2R^7$, an optionally substituted C1-C6 alkyl group, or an optionally substituted C3-C7 cycloalkyl group;

R^4 is a hydrogen atom, an optionally substituted C1-C6 alkyl group, an optionally substituted C3-C7 cycloalkyl group, or an optionally substituted carbonylamino group;

R^5 is an optionally substituted C1-C6 alkyl group, an optionally substituted C3-C7 cycloalkyl group, an optionally substituted C1-C6 alkoxy group, an optionally substituted amino group, an optionally substituted 4- to 10-membered monocyclic or polycyclic saturated heterocyclic group, an optionally substituted 5- to 10-membered monocyclic or polycyclic unsaturated heterocyclic group, or an optionally substituted 6- to 10-membered monocyclic or polycyclic aromatic hydrocarbon group;

R^6 is a hydrogen atom, an optionally substituted C1-C6 alkyl group, an optionally substituted C1-C6 mono- or di-alkylamino group, an optionally substituted C3-C7 cycloalkyl group, or an optionally substituted 4- to 10-membered monocyclic or polycyclic saturated heterocyclic group having 1 to 4 heteroatoms selected from a nitrogen atom, an oxygen atom and a sulfur atom;

R^7 is an optionally substituted C1-C6 alkyl group, an optionally substituted C3-C7 cycloalkyl group, an optionally substituted 5- to 10-membered saturated or unsaturated heterocyclic group, or an optionally substituted 6- to 10-membered aromatic

hydrocarbon group;

the ring A is bicyclo[2.2.1]heptane or bicyclo[2.2.2]octane; and

n represents an integer of 0 to 3;

or a pharmaceutically acceptable salt thereof.

2. The compound or pharmaceutically acceptable salt thereof according to claim 1, wherein R^1 is a hydrogen atom or a C1-C3 alkyl group.

3. The compound or pharmaceutically acceptable salt thereof according to claim 1 or 2, wherein X is NR^2R^3, OR^4 or a 5- to 7-membered monocyclic saturated or unsaturated heterocyclic group having 1 to 3 heteroatoms selected from a nitrogen atom, an oxygen atom and a sulfur atom;

R^2 is a hydrogen atom or a C1-C6 alkyl group;

R^3 is $C(=O)R^5$, $C(=S)R^6$ or a C1-C6 alkyl group (which may have, as a substituent, a cyano group, a halogen atom or a 5- to 7-membered monocyclic unsaturated heterocyclic group having 1 to 3 heteroatoms selected from a nitrogen atom, an oxygen atom and a sulfur atom);

R^4 is a hydrogen atom;

R^5 is an optionally substituted C1-C6 alkyl group, a C1-C6 alkoxy group, a C1-C6 mono- or di-alkylamino group, an optionally substituted 5- to 10-membered monocyclic or polycyclic unsaturated heterocyclic group, or a 6- to 10-membered monocyclic or polycyclic aromatic hydrocarbon group; and

R^6 is a C1-C6 mono- or di-alkylamino group, or a 4- to 10-membered monocyclic or polycyclic saturated heterocyclic group having 1 to 4 heteroatoms selected from a nitrogen atom, an oxygen atom and a sulfur atom, which may have a C1-C6 alkyl group.

4. The compound or pharmaceutically acceptable salt thereof according to any one of claims 1 to 3, wherein n is 0 or 1.

5. The compound or pharmaceutically acceptable salt thereof according to any one of claims 1 to 4, wherein R^1 is a hydrogen atom.

6. The compound or pharmaceutically acceptable salt thereof according to any one of claims 1 to 5, wherein X is NR^2R^3 or a 5- to 7-membered monocyclic saturated or unsaturated heterocyclic group having 1 to 3 heteroatoms selected from a nitrogen atom, an oxygen atom and a sulfur atom;

R^2 is a hydrogen atom;

R^3 is $C(=O)R^5$; and

R^5 is an optionally substituted C1-C6 alkyl group, a C1-C6 alkoxy group, a C1-C6 mono- or di-alkylamino group, an optionally substituted 5- to 10-membered

monocyclic or polycyclic unsaturated heterocyclic group, or a 6- to 10-membered monocyclic or polycyclic aromatic hydrocarbon group.

7. The compound or pharmaceutically acceptable salt thereof according to any one of claims 1 to 6, wherein X is NR^2R^3 or a 5- to 7-membered monocyclic saturated heterocyclic group having 1 to 3 heteroatoms selected from a nitrogen atom, an oxygen atom and a sulfur atom;

R^2 is a hydrogen atom;

R^3 is $C(=O)R^5$; and

R^5 is a C1-C6 alkyl group which may have a halogen atom, or a 5- to 10-membered monocyclic or polycyclic fully unsaturated or partially saturated heterocyclic group having 1 to 4 heteroatoms selected from a nitrogen atom, an oxygen atom and a sulfur atom, which may have a C1-C6 alkyl group.

8. The compound or pharmaceutically acceptable salt thereof according to any one of claims 1 to 7, wherein the ring A is bicyclo[2.2.1]heptane.

9. The compound or pharmaceutically acceptable salt thereof according to any one of claims 1 to 8, wherein n is 0.

10. The compound or pharmaceutically acceptable salt thereof according to any one of claims 1 to 9, wherein the substituent~~s~~ for a C1-C3 alkyl group as R^1, a monocyclic or polycyclic saturated or unsaturated heterocyclic group as X, a C1-C6 alkyl as R^2, a C1-C6 alkyl group as R^3, a C3-C7 cycloalkyl group as R^3, a C1-C6 alkyl group as R^4, a C3-C7 cycloalkyl group as R^4, a carbonylamino group as R^4, a C1-C6 alkyl group as R^5, a C3-C7 cycloalkyl group as R^5, a C1-C6 alkoxy group as R^5, an amino group as R^5, a 4- to 10-membered monocyclic or polycyclic saturated heterocyclic group as R^5, a 5- to 10-membered monocyclic or polycyclic unsaturated heterocyclic group as R^5, a 6- to 10-membered monocyclic or polycyclic aromatic hydrocarbon as R^5, a C1-C6 alkyl group as R^6, a C1-C6 mono- or di-alkylamino group as R^6, a C3-C7 cycloalkyl group as R^6, a 4- to 10-membered monocyclic or polycyclic saturated heterocyclic group having 1 to 4 heteroatoms selected from a nitrogen atom, an oxygen atom and a sulfur atom as R^6, a C1-C6 alkyl group as R^7, a C3-C7 cycloalkyl group as R^7, a 5- to 10-membered saturated or unsaturated heterocyclic group as R^7, or a 6- to 10-membered aromatic hydrocarbon group as R^7 is ~~are each~~ selected from a halogen atom, a cyano group, a nitro group, an amino group, a hydroxyl group, an alkyl group, a haloalkyl group, a cycloalkyl group, an aralkyl group, an alkoxy group, a methylsulfonyl group, an alkoxyalkyl group, a hydroxyalkyl group, a fluoromethoxy group, a mono- or di-alkylamino group, a mono- or di-alkylaminoalkyl group, a carbonylamino group, an oxo group, an oxide group, a carboxyl group, an alkoxycarbonyl group, a phosphine oxide group, a saturated or unsaturated heterocyclic

group, a heterocyclic alkyl group and an aromatic hydrocarbon group.

11. A compound selected from the following group of compounds:

(1) 6-ethynyl-7-(4-morpholinobicyclo[2.2.1]heptan-1-yl)-5-(quinolin-3-yl)-7H-pyrrolo[2,3-d]pyrimidine-4-amine,

(2) N-(4-(4-amino-6-ethynyl-5-(quinolin-3-yl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)bicyclo[2.2.1]heptan-1-yl)-1-methyl-1H-pyrazole-5-carboxamide,

(3) N-(4-(4-amino-6-ethynyl-5-(quinolin-3-yl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)bicyclo[2.2.1]heptan-1-yl)-2,2-difluoroacetamide,

(4) N-(4-(4-amino-6-ethynyl-5-(quinolin-3-yl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)bicyclo[2.2.1]heptan-1-yl)-5-methyl-1,2,4-oxadiazole-3-carboxamide,

(5) N-(4-(4-amino-6-ethynyl-5-(quinolin-3-yl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)bicyclo[2.2.1]heptan-1-yl)-5-methylpyrazine-2-carboxamide,

(6) N-(4-(4-amino-6-ethynyl-5-(quinolin-3-yl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)bicyclo[2.2.1]heptan-1-yl)oxazole-2-carboxamide,

(7) N-(4-(4-amino-6-ethynyl-5-(quinolin-3-yl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)bicyclo[2.2.1]heptan-1-yl)pyrazine-2-carboxamide,

(8) N-(4-(4-amino-6-ethynyl-5-(quinolin-3-yl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)bicyclo[2.2.1]heptan-1-yl)pyridazine-3-carboxamide,

(9) N-(4-(4-amino-6-ethynyl-5-(quinolin-3-yl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)bicyclo[2.2.1]heptan-1-yl)pyrimidine-5-carboxamide,

(10) N-(4-(4-amino-6-ethynyl-5-(quinolin-3-yl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)bicyclo[2.2.1]heptan-1-yl)-1-cyclopropyl-1H-pyrazole-5-carboxamide, and

(11) N-(4-(4-amino-6-ethynyl-5-(quinolin-3-yl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)bicyclo[2.2.1]heptan-1-yl)isoxazole-5-carboxamide;

or a pharmaceutically acceptable salt thereof.

12. An antitumor agent comprising the compound or pharmaceutically acceptable salt thereof according to any one of claims 1 to 11, as an active ingredient.

13. A pharmaceutical composition comprising the compound or pharmaceutically acceptable salt thereof according to any one of claims 1 to 11, and a pharmaceutically acceptable carrier.

14. The compound or pharmaceutically acceptable salt thereof according to any one of claims 1 to 11, for use in the treatment of a tumor.

15. The use of the compound or pharmaceutically acceptable salt thereof according to any one of claims 1 to 11, in the manufacture of a medicament for the treatment of a tumor.